The impact of identifying laryngeal obstruction syndromes on reducing treatment of pediatric asthma: A systematic review.

Publication Year: 2022

DOI:
10.1002/ppul.25910

PMCID:
PMC9321614

PMID:
35355450

Journal Information

Full Title: Pediatr Pulmonol

Abbreviation: Pediatr Pulmonol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICTS OF INTEREST The authors declare no conflicts of interest."

Evidence found in paper:

"We would like to thank Dr. Miles Weinberger, Professor Emeritus of Pediatrics at the University of Iowa, for providing advice and permission to use his own summary information on clinical characteristics of inducible laryngeal obstruction subtypes and asthma, throughout the text and adapted in Table 5. We would also like to thank the University of Alberta Department of Pediatrics for providing funding for open access publicaiton of this study."

Evidence found in paper:

"This systematic review follows the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines, (Table ). The study protocol was registered with PROSPERO (CRD42020209168). Inducible laryngeal obstruction (ILO) in children is underrecognized. This systematic review characterizes the scientific evidence on the impact of pediatric ILO diagnosis and treatment on asthma medication use. This review, registered with PROSPERO (CRD42020209168), utilized database searches in MEDLINE, EMBASE, CINAHL, and Web of Science from inception to October 2020. Both experimental and observational studies on ILO and asthma outcomes in patients ≤18 years were included. Population characteristics (sample size, sex, age, and comorbidities) and study outcomes (medication usage and respiratory symptoms) were extracted. The risk of bias was assessed with the National Toxicology Program's Office of Health Assessment and Risk of Bias Rating Tool. Data are presented narratively due to study heterogeneity. Of 1091 studies, 1076 titles and abstracts were screened after duplicate removal. Screening 31 full texts yielded eight pre–post studies. Patients were an average of 14.1 years old, 15% male, and >90% used asthma medication; 40% reported allergies, 30% gastroesophageal reflux, and 20% anxiety or depression. Most patients received at least one intervention, with 75% showing symptomatic improvement and >75% decreasing or stopping asthma medications. Studies were small with a high risk of selection, confounding, and detection bias. Asthma management was not a primary outcome in any of the studies. Overall, ILO patients were often diagnosed with or treated for asthma before ILO diagnosis. Evidence from individual studies suggests that comorbidities including ILO, gastroesophageal reflux, allergies, and anxiety should be considered in pediatric patients with asthma not responsive to medical therapy. Further research is required to determine the proportion of impacted asthma patients."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025